Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia

Pfizer will soon market Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia.

Geodon will be widely used because it appears to cause less weight gain than other atypicals...Zyprexa, Risperdal, or Seroquel.

Weight gain causes some patients to discontinue therapy...and it increases the risk of developing diabetes and heart disease.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote